FDA Approves Two New Antibiotics to Combat Drug-Resistant Gonorrhea

In a major breakthrough, the US Food and Drug Administration (FDA) has approved two new antibiotics to treat uncomplicated urogenital gonorrhea in adults and children over 12 years.The drugs, Nuzolvence and Gepotidacin, were developed to combat the rising threat of drug-resistant strains of this common sexually transmitted infection (STI).Nuzolvence was developed through a global effort involving the Global Antibiotic Research & Development Partnership (GARDP).